Brief: Olema Oncology Q4 Net Income USD -26.772 Million
11/03/2024 20:03
Mar 11 (Reuters) - Olema Oncology Q4 basic EPS USD -0.49 vs. IBES estimate USD -0.48. * Q4 operating expenses USD 30.416 million * Q4 income from operations USD -30.416 million
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs